For the estimated 2.8 million Americans suffering from treatment-resistant depression (TRD), the arrival of esketamine nasal spray in 2019 couldn’t come soon enough. The FDA’s decision to approve the drug, the first ketamine-based antidepressant, was the latest chapter in ketamine’s journey from anesthetic to club drug to antidepressant. It was also the result of two decades of research, including by Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai, and James Murrough, MD, PhD, Director of the Depression and Anxiety Center for Discovery and Treatment. On Road to Resilience, Dr. Murrough explains about how ketamine differs from existing antidepressants and shares actionable insights into the neurobiology of depression.
Dr. James Murrough, MD, PhD, is Associate Professor of Psychiatry and Neuroscience and Director of the Depression and Anxiety Center for Discovery and Treatment at the Icahn School of Medicine at Mount Sinai.
Hear more resilience insights
[ Ссылка ]
Five Things to Know About Esketamine (with Dr. Murrough)
[ Ссылка ]
Depression and Anxiety Center for Discovery and Treatment (DAC)
[ Ссылка ]
Follow the Depression and Anxiety Center on Twitter
[ Ссылка ]
Department of Psychiatry at the Icahn School of Medicine
[ Ссылка ]
Follow Mount Sinai Psychiatry on Twitter
[ Ссылка ]
For photos, links, and transcripts of all our episodes, visit www.mountsinai.org/rtr
Road to Resilience is a podcast that brings you stories and insights to help you thrive in a challenging world. From fighting burnout and trauma, to building resilient families and communities, we explore what’s possible when science meets the human spirit. Powered by the Mount Sinai Health System.
Listen and subscribe to Road to Resilience on:
Apple Podcasts [ Ссылка ]
Spotify [ Ссылка ]
Google Podcasts [ Ссылка ]
Stitcher [ Ссылка ]
Pocket Casts [ Ссылка ]
YouTube [ Ссылка ]
